FierceBiotech November 2013

FailedDrugsThe true cost of drugs that fail in clinical trials should be measured by far more than the cash poured into the development process. Everyone loses something, whether it be the patients who are waiting for new treatments or the companies losing resources that could have gone back into bolstering R&D.

Some of the investment into these failed or shelved drugs can be recouped by giving them a second and often lower-risk chance in a new indication. This is known as drug repositioning, drug repurposing or drug rescue. It may be carried out by the company that invented the drug, but it’s more commonly pursued these days by smaller, more specialized companies.  

Read more

Sign up for our eNewsletter today!


First Name

Cures Within Reach


Wednesday the 17th. copyright 2015 Cures Within Reach.